Global Rheumatoid Arthritis Drugs Market Size, Share, Growth, Trends, Company Analysis and Forecast 2019-2026

CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. MARKET SHARE ANALYSIS/TOP PLAYER POSITIONING, 2016
3.4.  PORTER’S FIVE FORCES ANALYSIS
3.5. MARKET DYNAMICS

3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities

CHAPTER 4 GLOBAL RHEUMATOID ARTHRITIS (RA) DRUGS MARKET, BY DRUG CLASS

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS)

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. NON-STEROIDAL ANTI- INFLAMMATORY DRUGS (NSAIDS)

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

4.4. CORTICOSTEROIDS

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast

4.5. ANALGESICS

4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast

CHAPTER 5 GLOBAL RHEUMATOID ARTHRITIS (RA) DRUGS MARKET, BY ROUTE OF ADMINISTRATION

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. ORAL

5.2.1. Market size and forecast

5.3. PARENTERAL

5.3.1. Market size and forecast

CHAPTER 6 GLOBAL RHEUMATOID ARTHRITIS (RA) DRUGS MARKET, BY REGION

6.1. OVERVIEW
6.2. NORTH AMERICA

6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast

6.2.3.1. U.S. market size and forecast
6.2.3.2. Canada market size and forecast
6.2.3.3. Mexico market size and forecast

6.2.4. North America Rheumatoid Arthritis (RA) Drugs Market by Drug Class
6.2.5. North America Rheumatoid Arthritis (RA) Drugs Market by Route of Administration

6.3. EUROPE

6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast

6.3.3.1. Germany market size and forecast
6.3.3.2. France market size and forecast
6.3.3.3. UK market size and forecast
6.3.3.4. Italy market size and forecast
6.3.3.5. Spain market size and forecast
6.3.3.6. Rest of Europe market size and forecast

6.3.4. Europe Rheumatoid Arthritis (RA) Drugs Market by Drug Class
6.3.5. Europe Rheumatoid Arthritis (RA) Drugs Market by Route of Administration

6.4. ASIA-PACIFIC

6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast

6.4.3.1. Japan market size and forecast
6.4.3.2. China market size and forecast
6.4.3.3. Australia market size and forecast
6.4.3.4. India market size and forecast
6.4.3.5. Rest of Asia-Pacific market size and forecast

6.4.4. Asia-Pacific Rheumatoid Arthritis (RA) Drugs Market by Drug Class
6.4.5. Asia-Pacific Rheumatoid Arthritis (RA) Drugs Market by Route of Administration

6.5. LAMEA

6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast

6.5.3.1. Brazil market size and forecast
6.5.3.2. Saudi Arabia market size and forecast
6.5.3.3. Argentina market size and forecast
6.5.3.4. South Africa market size and forecast
6.5.3.5. Rest of LAMEA market size and forecast

6.5.4. LAMEA Rheumatoid Arthritis (RA) Drugs Market by Drug Class
6.5.5. LAMEA Rheumatoid Arthritis (RA) Drugs Market by Route of Administration

CHAPTER 7 COMPANY PROFILES

7.1. ABBVIE

7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments

7.2. BIOGEN, INC.

7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments

7.3. BRISTOL-MYERS SQUIBB

7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments

7.4. CELGENE CORPORATION

7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments

7.5. CELLTRION INC.

7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments

7.6. JOHNSON & JOHNSON

7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments

7.7. MEDIMMUNE, LLC

7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments

7.8. MERCK & CO., INC.

7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments

7.9. NOVARTIS INTERNATIONAL AG

7.9.1. Operating business segments
7.9.2. Business performance
7.9.3. Key strategic moves and developments

7.10. TAKEDA PHARMACEUTICAL COMPANY LTD.

7.10.1. Operating business segments
7.10.2. Business performance
7.10.3. Key strategic moves and developments

Report Details

  • Report Code:28883
  • Category:Healthcare
  • No. of Pages:140
  • Format:PDF/PPT/Excel
  • Published:August 2019
  • Historical Year:2021-2022
  • Base Year:2023
  • Estimated Year:2024-2033

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers